Vanguard Group Inc. raised its stake in BioScrip, Inc. (NASDAQ:BIOS) by 3.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,495,029 shares of the company’s stock after buying an additional 146,980 shares during the quarter. Vanguard Group Inc. owned about 3.72% of BioScrip worth $12,204,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in BIOS. Bank of New York Mellon Corp increased its holdings in BioScrip by 7.6% during the first quarter. Bank of New York Mellon Corp now owns 475,844 shares of the company’s stock worth $809,000 after buying an additional 33,453 shares during the last quarter. American International Group Inc. increased its holdings in BioScrip by 73.8% during the first quarter. American International Group Inc. now owns 67,812 shares of the company’s stock worth $115,000 after buying an additional 28,787 shares during the last quarter. FMR LLC increased its holdings in BioScrip by 36.1% during the first quarter. FMR LLC now owns 4,803,000 shares of the company’s stock worth $8,165,000 after buying an additional 1,273,205 shares during the last quarter. California Public Employees Retirement System increased its holdings in BioScrip by 37.5% during the first quarter. California Public Employees Retirement System now owns 663,700 shares of the company’s stock worth $1,128,000 after buying an additional 181,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in BioScrip by 15.3% during the first quarter. Geode Capital Management LLC now owns 944,054 shares of the company’s stock worth $1,604,000 after buying an additional 125,098 shares during the last quarter. 84.69% of the stock is currently owned by hedge funds and other institutional investors.
BIOS has been the topic of a number of recent analyst reports. ValuEngine upgraded shares of BioScrip from a “strong sell” rating to a “sell” rating in a report on Thursday, November 9th. SunTrust Banks reiterated a “buy” rating and issued a $3.00 price objective on shares of BioScrip in a report on Friday, November 3rd. BidaskClub downgraded shares of BioScrip from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Zacks Investment Research downgraded shares of BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, Jefferies Group reiterated a “buy” rating and issued a $4.00 price objective (up from $3.00) on shares of BioScrip in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $3.60.
BioScrip (NASDAQ:BIOS) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.02). The company had revenue of $198.70 million for the quarter, compared to analyst estimates of $202.91 million. During the same period last year, the company earned ($0.12) earnings per share. The firm’s revenue for the quarter was down 11.5% compared to the same quarter last year. analysts predict that BioScrip, Inc. will post -0.63 EPS for the current year.
In related news, Director Coliseum Capital Management, L sold 2,846,941 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $2.93, for a total transaction of $8,341,537.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel E. Greenleaf bought 15,000 shares of the company’s stock in a transaction dated Thursday, November 9th. The stock was bought at an average cost of $2.03 per share, with a total value of $30,450.00. Following the acquisition, the chief executive officer now directly owns 31,000 shares of the company’s stock, valued at approximately $62,930. The disclosure for this purchase can be found here. Corporate insiders own 0.80% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Vanguard Group Inc. Purchases 146,980 Shares of BioScrip, Inc. (BIOS)” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/12/06/bioscrip-inc-bios-shares-bought-by-vanguard-group-inc.html.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.